Global Vaccine Conjugate Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our LPI (LP Information) latest study, the global Vaccine Conjugate market size was valued at US$ 9978.2 million in 2023. With growing demand in downstream market, the Vaccine Conjugate is forecast to a readjusted size of US$ 12630 million by 2030 with a CAGR of 3.4% during review period.
The research report highlights the growth potential of the global Vaccine Conjugate market. Vaccine Conjugate are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Vaccine Conjugate. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Vaccine Conjugate market.
Vaccines are used to prevent diseases by invoking an immune response to an antigen, the foreign part of a bacteria or virus that the immune system recognizes. Conjugate vaccines combine a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.
North America is the largest supplier of Conjugate Vaccine, with a production market share nearly 65. Europe is the second largest supplier of Conjugate Vaccine, enjoying production market share nearly 26.
Key Features:
The report on Vaccine Conjugate market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Vaccine Conjugate market. It may include historical data, market segmentation by Type (e.g., Hib Vaccine, Meningococcal Vaccine), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Vaccine Conjugate market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Vaccine Conjugate market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Vaccine Conjugate industry. This include advancements in Vaccine Conjugate technology, Vaccine Conjugate new entrants, Vaccine Conjugate new investment, and other innovations that are shaping the future of Vaccine Conjugate.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Vaccine Conjugate market. It includes factors influencing customer ' purchasing decisions, preferences for Vaccine Conjugate product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Vaccine Conjugate market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Vaccine Conjugate market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Vaccine Conjugate market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Vaccine Conjugate industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Vaccine Conjugate market.
Market Segmentation:
Vaccine Conjugate market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
What is the 10-year outlook for the global Vaccine Conjugate market?
What factors are driving Vaccine Conjugate market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Vaccine Conjugate market opportunities vary by end market size?
How does Vaccine Conjugate break out type, application?
According to our LPI (LP Information) latest study, the global Vaccine Conjugate market size was valued at US$ 9978.2 million in 2023. With growing demand in downstream market, the Vaccine Conjugate is forecast to a readjusted size of US$ 12630 million by 2030 with a CAGR of 3.4% during review period.
The research report highlights the growth potential of the global Vaccine Conjugate market. Vaccine Conjugate are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Vaccine Conjugate. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Vaccine Conjugate market.
Vaccines are used to prevent diseases by invoking an immune response to an antigen, the foreign part of a bacteria or virus that the immune system recognizes. Conjugate vaccines combine a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.
North America is the largest supplier of Conjugate Vaccine, with a production market share nearly 65. Europe is the second largest supplier of Conjugate Vaccine, enjoying production market share nearly 26.
Key Features:
The report on Vaccine Conjugate market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Vaccine Conjugate market. It may include historical data, market segmentation by Type (e.g., Hib Vaccine, Meningococcal Vaccine), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Vaccine Conjugate market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Vaccine Conjugate market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Vaccine Conjugate industry. This include advancements in Vaccine Conjugate technology, Vaccine Conjugate new entrants, Vaccine Conjugate new investment, and other innovations that are shaping the future of Vaccine Conjugate.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Vaccine Conjugate market. It includes factors influencing customer ' purchasing decisions, preferences for Vaccine Conjugate product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Vaccine Conjugate market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Vaccine Conjugate market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Vaccine Conjugate market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Vaccine Conjugate industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Vaccine Conjugate market.
Market Segmentation:
Vaccine Conjugate market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
- Hib Vaccine
- Meningococcal Vaccine
- Pneumococcal Vaccine
- Others
- Children
- Adult
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Pfizer
- GSK
- Sanofi
- Merck
- Walvax Biotechnology
- Royal (Wuxi) Bio-Pharmaceutical
- Bharat Biotech
- Zhifei Biologic
- Chengdu Olymvax Biopharmaceuticals
- Beijing Minhai Biotechnology
- CanSinoBIO
- Beijing Xiangrui Biological Products
What is the 10-year outlook for the global Vaccine Conjugate market?
What factors are driving Vaccine Conjugate market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Vaccine Conjugate market opportunities vary by end market size?
How does Vaccine Conjugate break out type, application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Vaccine Conjugate Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Vaccine Conjugate by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Vaccine Conjugate by Country/Region, 2019, 2023 & 2030
2.2 Vaccine Conjugate Segment by Type
2.2.1 Hib Vaccine
2.2.2 Meningococcal Vaccine
2.2.3 Pneumococcal Vaccine
2.2.4 Others
2.3 Vaccine Conjugate Sales by Type
2.3.1 Global Vaccine Conjugate Sales Market Share by Type (2019-2024)
2.3.2 Global Vaccine Conjugate Revenue and Market Share by Type (2019-2024)
2.3.3 Global Vaccine Conjugate Sale Price by Type (2019-2024)
2.4 Vaccine Conjugate Segment by Application
2.4.1 Children
2.4.2 Adult
2.5 Vaccine Conjugate Sales by Application
2.5.1 Global Vaccine Conjugate Sale Market Share by Application (2019-2024)
2.5.2 Global Vaccine Conjugate Revenue and Market Share by Application (2019-2024)
2.5.3 Global Vaccine Conjugate Sale Price by Application (2019-2024)
3 GLOBAL VACCINE CONJUGATE BY COMPANY
3.1 Global Vaccine Conjugate Breakdown Data by Company
3.1.1 Global Vaccine Conjugate Annual Sales by Company (2019-2024)
3.1.2 Global Vaccine Conjugate Sales Market Share by Company (2019-2024)
3.2 Global Vaccine Conjugate Annual Revenue by Company (2019-2024)
3.2.1 Global Vaccine Conjugate Revenue by Company (2019-2024)
3.2.2 Global Vaccine Conjugate Revenue Market Share by Company (2019-2024)
3.3 Global Vaccine Conjugate Sale Price by Company
3.4 Key Manufacturers Vaccine Conjugate Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Vaccine Conjugate Product Location Distribution
3.4.2 Players Vaccine Conjugate Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR VACCINE CONJUGATE BY GEOGRAPHIC REGION
4.1 World Historic Vaccine Conjugate Market Size by Geographic Region (2019-2024)
4.1.1 Global Vaccine Conjugate Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Vaccine Conjugate Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Vaccine Conjugate Market Size by Country/Region (2019-2024)
4.2.1 Global Vaccine Conjugate Annual Sales by Country/Region (2019-2024)
4.2.2 Global Vaccine Conjugate Annual Revenue by Country/Region (2019-2024)
4.3 Americas Vaccine Conjugate Sales Growth
4.4 APAC Vaccine Conjugate Sales Growth
4.5 Europe Vaccine Conjugate Sales Growth
4.6 Middle East & Africa Vaccine Conjugate Sales Growth
5 AMERICAS
5.1 Americas Vaccine Conjugate Sales by Country
5.1.1 Americas Vaccine Conjugate Sales by Country (2019-2024)
5.1.2 Americas Vaccine Conjugate Revenue by Country (2019-2024)
5.2 Americas Vaccine Conjugate Sales by Type
5.3 Americas Vaccine Conjugate Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Vaccine Conjugate Sales by Region
6.1.1 APAC Vaccine Conjugate Sales by Region (2019-2024)
6.1.2 APAC Vaccine Conjugate Revenue by Region (2019-2024)
6.2 APAC Vaccine Conjugate Sales by Type
6.3 APAC Vaccine Conjugate Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Vaccine Conjugate by Country
7.1.1 Europe Vaccine Conjugate Sales by Country (2019-2024)
7.1.2 Europe Vaccine Conjugate Revenue by Country (2019-2024)
7.2 Europe Vaccine Conjugate Sales by Type
7.3 Europe Vaccine Conjugate Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Vaccine Conjugate by Country
8.1.1 Middle East & Africa Vaccine Conjugate Sales by Country (2019-2024)
8.1.2 Middle East & Africa Vaccine Conjugate Revenue by Country (2019-2024)
8.2 Middle East & Africa Vaccine Conjugate Sales by Type
8.3 Middle East & Africa Vaccine Conjugate Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Vaccine Conjugate
10.3 Manufacturing Process Analysis of Vaccine Conjugate
10.4 Industry Chain Structure of Vaccine Conjugate
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Vaccine Conjugate Distributors
11.3 Vaccine Conjugate Customer
12 WORLD FORECAST REVIEW FOR VACCINE CONJUGATE BY GEOGRAPHIC REGION
12.1 Global Vaccine Conjugate Market Size Forecast by Region
12.1.1 Global Vaccine Conjugate Forecast by Region (2025-2030)
12.1.2 Global Vaccine Conjugate Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Vaccine Conjugate Forecast by Type
12.7 Global Vaccine Conjugate Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Vaccine Conjugate Product Portfolios and Specifications
13.1.3 Pfizer Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 GSK
13.2.1 GSK Company Information
13.2.2 GSK Vaccine Conjugate Product Portfolios and Specifications
13.2.3 GSK Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 GSK Main Business Overview
13.2.5 GSK Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi Vaccine Conjugate Product Portfolios and Specifications
13.3.3 Sanofi Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 Merck
13.4.1 Merck Company Information
13.4.2 Merck Vaccine Conjugate Product Portfolios and Specifications
13.4.3 Merck Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Merck Main Business Overview
13.4.5 Merck Latest Developments
13.5 Walvax Biotechnology
13.5.1 Walvax Biotechnology Company Information
13.5.2 Walvax Biotechnology Vaccine Conjugate Product Portfolios and Specifications
13.5.3 Walvax Biotechnology Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Walvax Biotechnology Main Business Overview
13.5.5 Walvax Biotechnology Latest Developments
13.6 Royal (Wuxi) Bio-Pharmaceutical
13.6.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
13.6.2 Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Product Portfolios and Specifications
13.6.3 Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Royal (Wuxi) Bio-Pharmaceutical Main Business Overview
13.6.5 Royal (Wuxi) Bio-Pharmaceutical Latest Developments
13.7 Bharat Biotech
13.7.1 Bharat Biotech Company Information
13.7.2 Bharat Biotech Vaccine Conjugate Product Portfolios and Specifications
13.7.3 Bharat Biotech Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Bharat Biotech Main Business Overview
13.7.5 Bharat Biotech Latest Developments
13.8 Zhifei Biologic
13.8.1 Zhifei Biologic Company Information
13.8.2 Zhifei Biologic Vaccine Conjugate Product Portfolios and Specifications
13.8.3 Zhifei Biologic Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Zhifei Biologic Main Business Overview
13.8.5 Zhifei Biologic Latest Developments
13.9 Chengdu Olymvax Biopharmaceuticals
13.9.1 Chengdu Olymvax Biopharmaceuticals Company Information
13.9.2 Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Product Portfolios and Specifications
13.9.3 Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Chengdu Olymvax Biopharmaceuticals Main Business Overview
13.9.5 Chengdu Olymvax Biopharmaceuticals Latest Developments
13.10 Beijing Minhai Biotechnology
13.10.1 Beijing Minhai Biotechnology Company Information
13.10.2 Beijing Minhai Biotechnology Vaccine Conjugate Product Portfolios and Specifications
13.10.3 Beijing Minhai Biotechnology Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Beijing Minhai Biotechnology Main Business Overview
13.10.5 Beijing Minhai Biotechnology Latest Developments
13.11 CanSinoBIO
13.11.1 CanSinoBIO Company Information
13.11.2 CanSinoBIO Vaccine Conjugate Product Portfolios and Specifications
13.11.3 CanSinoBIO Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 CanSinoBIO Main Business Overview
13.11.5 CanSinoBIO Latest Developments
13.12 Beijing Xiangrui Biological Products
13.12.1 Beijing Xiangrui Biological Products Company Information
13.12.2 Beijing Xiangrui Biological Products Vaccine Conjugate Product Portfolios and Specifications
13.12.3 Beijing Xiangrui Biological Products Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Beijing Xiangrui Biological Products Main Business Overview
13.12.5 Beijing Xiangrui Biological Products Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Vaccine Conjugate Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Vaccine Conjugate by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Vaccine Conjugate by Country/Region, 2019, 2023 & 2030
2.2 Vaccine Conjugate Segment by Type
2.2.1 Hib Vaccine
2.2.2 Meningococcal Vaccine
2.2.3 Pneumococcal Vaccine
2.2.4 Others
2.3 Vaccine Conjugate Sales by Type
2.3.1 Global Vaccine Conjugate Sales Market Share by Type (2019-2024)
2.3.2 Global Vaccine Conjugate Revenue and Market Share by Type (2019-2024)
2.3.3 Global Vaccine Conjugate Sale Price by Type (2019-2024)
2.4 Vaccine Conjugate Segment by Application
2.4.1 Children
2.4.2 Adult
2.5 Vaccine Conjugate Sales by Application
2.5.1 Global Vaccine Conjugate Sale Market Share by Application (2019-2024)
2.5.2 Global Vaccine Conjugate Revenue and Market Share by Application (2019-2024)
2.5.3 Global Vaccine Conjugate Sale Price by Application (2019-2024)
3 GLOBAL VACCINE CONJUGATE BY COMPANY
3.1 Global Vaccine Conjugate Breakdown Data by Company
3.1.1 Global Vaccine Conjugate Annual Sales by Company (2019-2024)
3.1.2 Global Vaccine Conjugate Sales Market Share by Company (2019-2024)
3.2 Global Vaccine Conjugate Annual Revenue by Company (2019-2024)
3.2.1 Global Vaccine Conjugate Revenue by Company (2019-2024)
3.2.2 Global Vaccine Conjugate Revenue Market Share by Company (2019-2024)
3.3 Global Vaccine Conjugate Sale Price by Company
3.4 Key Manufacturers Vaccine Conjugate Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Vaccine Conjugate Product Location Distribution
3.4.2 Players Vaccine Conjugate Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR VACCINE CONJUGATE BY GEOGRAPHIC REGION
4.1 World Historic Vaccine Conjugate Market Size by Geographic Region (2019-2024)
4.1.1 Global Vaccine Conjugate Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Vaccine Conjugate Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Vaccine Conjugate Market Size by Country/Region (2019-2024)
4.2.1 Global Vaccine Conjugate Annual Sales by Country/Region (2019-2024)
4.2.2 Global Vaccine Conjugate Annual Revenue by Country/Region (2019-2024)
4.3 Americas Vaccine Conjugate Sales Growth
4.4 APAC Vaccine Conjugate Sales Growth
4.5 Europe Vaccine Conjugate Sales Growth
4.6 Middle East & Africa Vaccine Conjugate Sales Growth
5 AMERICAS
5.1 Americas Vaccine Conjugate Sales by Country
5.1.1 Americas Vaccine Conjugate Sales by Country (2019-2024)
5.1.2 Americas Vaccine Conjugate Revenue by Country (2019-2024)
5.2 Americas Vaccine Conjugate Sales by Type
5.3 Americas Vaccine Conjugate Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Vaccine Conjugate Sales by Region
6.1.1 APAC Vaccine Conjugate Sales by Region (2019-2024)
6.1.2 APAC Vaccine Conjugate Revenue by Region (2019-2024)
6.2 APAC Vaccine Conjugate Sales by Type
6.3 APAC Vaccine Conjugate Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Vaccine Conjugate by Country
7.1.1 Europe Vaccine Conjugate Sales by Country (2019-2024)
7.1.2 Europe Vaccine Conjugate Revenue by Country (2019-2024)
7.2 Europe Vaccine Conjugate Sales by Type
7.3 Europe Vaccine Conjugate Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Vaccine Conjugate by Country
8.1.1 Middle East & Africa Vaccine Conjugate Sales by Country (2019-2024)
8.1.2 Middle East & Africa Vaccine Conjugate Revenue by Country (2019-2024)
8.2 Middle East & Africa Vaccine Conjugate Sales by Type
8.3 Middle East & Africa Vaccine Conjugate Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Vaccine Conjugate
10.3 Manufacturing Process Analysis of Vaccine Conjugate
10.4 Industry Chain Structure of Vaccine Conjugate
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Vaccine Conjugate Distributors
11.3 Vaccine Conjugate Customer
12 WORLD FORECAST REVIEW FOR VACCINE CONJUGATE BY GEOGRAPHIC REGION
12.1 Global Vaccine Conjugate Market Size Forecast by Region
12.1.1 Global Vaccine Conjugate Forecast by Region (2025-2030)
12.1.2 Global Vaccine Conjugate Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Vaccine Conjugate Forecast by Type
12.7 Global Vaccine Conjugate Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Vaccine Conjugate Product Portfolios and Specifications
13.1.3 Pfizer Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 GSK
13.2.1 GSK Company Information
13.2.2 GSK Vaccine Conjugate Product Portfolios and Specifications
13.2.3 GSK Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 GSK Main Business Overview
13.2.5 GSK Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi Vaccine Conjugate Product Portfolios and Specifications
13.3.3 Sanofi Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 Merck
13.4.1 Merck Company Information
13.4.2 Merck Vaccine Conjugate Product Portfolios and Specifications
13.4.3 Merck Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Merck Main Business Overview
13.4.5 Merck Latest Developments
13.5 Walvax Biotechnology
13.5.1 Walvax Biotechnology Company Information
13.5.2 Walvax Biotechnology Vaccine Conjugate Product Portfolios and Specifications
13.5.3 Walvax Biotechnology Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Walvax Biotechnology Main Business Overview
13.5.5 Walvax Biotechnology Latest Developments
13.6 Royal (Wuxi) Bio-Pharmaceutical
13.6.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
13.6.2 Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Product Portfolios and Specifications
13.6.3 Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Royal (Wuxi) Bio-Pharmaceutical Main Business Overview
13.6.5 Royal (Wuxi) Bio-Pharmaceutical Latest Developments
13.7 Bharat Biotech
13.7.1 Bharat Biotech Company Information
13.7.2 Bharat Biotech Vaccine Conjugate Product Portfolios and Specifications
13.7.3 Bharat Biotech Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Bharat Biotech Main Business Overview
13.7.5 Bharat Biotech Latest Developments
13.8 Zhifei Biologic
13.8.1 Zhifei Biologic Company Information
13.8.2 Zhifei Biologic Vaccine Conjugate Product Portfolios and Specifications
13.8.3 Zhifei Biologic Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Zhifei Biologic Main Business Overview
13.8.5 Zhifei Biologic Latest Developments
13.9 Chengdu Olymvax Biopharmaceuticals
13.9.1 Chengdu Olymvax Biopharmaceuticals Company Information
13.9.2 Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Product Portfolios and Specifications
13.9.3 Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Chengdu Olymvax Biopharmaceuticals Main Business Overview
13.9.5 Chengdu Olymvax Biopharmaceuticals Latest Developments
13.10 Beijing Minhai Biotechnology
13.10.1 Beijing Minhai Biotechnology Company Information
13.10.2 Beijing Minhai Biotechnology Vaccine Conjugate Product Portfolios and Specifications
13.10.3 Beijing Minhai Biotechnology Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Beijing Minhai Biotechnology Main Business Overview
13.10.5 Beijing Minhai Biotechnology Latest Developments
13.11 CanSinoBIO
13.11.1 CanSinoBIO Company Information
13.11.2 CanSinoBIO Vaccine Conjugate Product Portfolios and Specifications
13.11.3 CanSinoBIO Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 CanSinoBIO Main Business Overview
13.11.5 CanSinoBIO Latest Developments
13.12 Beijing Xiangrui Biological Products
13.12.1 Beijing Xiangrui Biological Products Company Information
13.12.2 Beijing Xiangrui Biological Products Vaccine Conjugate Product Portfolios and Specifications
13.12.3 Beijing Xiangrui Biological Products Vaccine Conjugate Sales, Revenue, Price and Gross Margin (2019-2024)
13.12.4 Beijing Xiangrui Biological Products Main Business Overview
13.12.5 Beijing Xiangrui Biological Products Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Vaccine Conjugate Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Vaccine Conjugate Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Hib Vaccine
Table 4. Major Players of Meningococcal Vaccine
Table 5. Major Players of Pneumococcal Vaccine
Table 6. Major Players of Others
Table 7. Global Vaccine Conjugate Sales by Type (2019-2024) & (K Doses)
Table 8. Global Vaccine Conjugate Sales Market Share by Type (2019-2024)
Table 9. Global Vaccine Conjugate Revenue by Type (2019-2024) & ($ million)
Table 10. Global Vaccine Conjugate Revenue Market Share by Type (2019-2024)
Table 11. Global Vaccine Conjugate Sale Price by Type (2019-2024) & (US$/Dose)
Table 12. Global Vaccine Conjugate Sales by Application (2019-2024) & (K Doses)
Table 13. Global Vaccine Conjugate Sales Market Share by Application (2019-2024)
Table 14. Global Vaccine Conjugate Revenue by Application (2019-2024)
Table 15. Global Vaccine Conjugate Revenue Market Share by Application (2019-2024)
Table 16. Global Vaccine Conjugate Sale Price by Application (2019-2024) & (US$/Dose)
Table 17. Global Vaccine Conjugate Sales by Company (2019-2024) & (K Doses)
Table 18. Global Vaccine Conjugate Sales Market Share by Company (2019-2024)
Table 19. Global Vaccine Conjugate Revenue by Company (2019-2024) ($ Millions)
Table 20. Global Vaccine Conjugate Revenue Market Share by Company (2019-2024)
Table 21. Global Vaccine Conjugate Sale Price by Company (2019-2024) & (US$/Dose)
Table 22. Key Manufacturers Vaccine Conjugate Producing Area Distribution and Sales Area
Table 23. Players Vaccine Conjugate Products Offered
Table 24. Vaccine Conjugate Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Vaccine Conjugate Sales by Geographic Region (2019-2024) & (K Doses)
Table 28. Global Vaccine Conjugate Sales Market Share Geographic Region (2019-2024)
Table 29. Global Vaccine Conjugate Revenue by Geographic Region (2019-2024) & ($ millions)
Table 30. Global Vaccine Conjugate Revenue Market Share by Geographic Region (2019-2024)
Table 31. Global Vaccine Conjugate Sales by Country/Region (2019-2024) & (K Doses)
Table 32. Global Vaccine Conjugate Sales Market Share by Country/Region (2019-2024)
Table 33. Global Vaccine Conjugate Revenue by Country/Region (2019-2024) & ($ millions)
Table 34. Global Vaccine Conjugate Revenue Market Share by Country/Region (2019-2024)
Table 35. Americas Vaccine Conjugate Sales by Country (2019-2024) & (K Doses)
Table 36. Americas Vaccine Conjugate Sales Market Share by Country (2019-2024)
Table 37. Americas Vaccine Conjugate Revenue by Country (2019-2024) & ($ Millions)
Table 38. Americas Vaccine Conjugate Revenue Market Share by Country (2019-2024)
Table 39. Americas Vaccine Conjugate Sales by Type (2019-2024) & (K Doses)
Table 40. Americas Vaccine Conjugate Sales by Application (2019-2024) & (K Doses)
Table 41. APAC Vaccine Conjugate Sales by Region (2019-2024) & (K Doses)
Table 42. APAC Vaccine Conjugate Sales Market Share by Region (2019-2024)
Table 43. APAC Vaccine Conjugate Revenue by Region (2019-2024) & ($ Millions)
Table 44. APAC Vaccine Conjugate Revenue Market Share by Region (2019-2024)
Table 45. APAC Vaccine Conjugate Sales by Type (2019-2024) & (K Doses)
Table 46. APAC Vaccine Conjugate Sales by Application (2019-2024) & (K Doses)
Table 47. Europe Vaccine Conjugate Sales by Country (2019-2024) & (K Doses)
Table 48. Europe Vaccine Conjugate Sales Market Share by Country (2019-2024)
Table 49. Europe Vaccine Conjugate Revenue by Country (2019-2024) & ($ Millions)
Table 50. Europe Vaccine Conjugate Revenue Market Share by Country (2019-2024)
Table 51. Europe Vaccine Conjugate Sales by Type (2019-2024) & (K Doses)
Table 52. Europe Vaccine Conjugate Sales by Application (2019-2024) & (K Doses)
Table 53. Middle East & Africa Vaccine Conjugate Sales by Country (2019-2024) & (K Doses)
Table 54. Middle East & Africa Vaccine Conjugate Sales Market Share by Country (2019-2024)
Table 55. Middle East & Africa Vaccine Conjugate Revenue by Country (2019-2024) & ($ Millions)
Table 56. Middle East & Africa Vaccine Conjugate Revenue Market Share by Country (2019-2024)
Table 57. Middle East & Africa Vaccine Conjugate Sales by Type (2019-2024) & (K Doses)
Table 58. Middle East & Africa Vaccine Conjugate Sales by Application (2019-2024) & (K Doses)
Table 59. Key Market Drivers & Growth Opportunities of Vaccine Conjugate
Table 60. Key Market Challenges & Risks of Vaccine Conjugate
Table 61. Key Industry Trends of Vaccine Conjugate
Table 62. Vaccine Conjugate Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Vaccine Conjugate Distributors List
Table 65. Vaccine Conjugate Customer List
Table 66. Global Vaccine Conjugate Sales Forecast by Region (2025-2030) & (K Doses)
Table 67. Global Vaccine Conjugate Revenue Forecast by Region (2025-2030) & ($ millions)
Table 68. Americas Vaccine Conjugate Sales Forecast by Country (2025-2030) & (K Doses)
Table 69. Americas Vaccine Conjugate Revenue Forecast by Country (2025-2030) & ($ millions)
Table 70. APAC Vaccine Conjugate Sales Forecast by Region (2025-2030) & (K Doses)
Table 71. APAC Vaccine Conjugate Revenue Forecast by Region (2025-2030) & ($ millions)
Table 72. Europe Vaccine Conjugate Sales Forecast by Country (2025-2030) & (K Doses)
Table 73. Europe Vaccine Conjugate Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. Middle East & Africa Vaccine Conjugate Sales Forecast by Country (2025-2030) & (K Doses)
Table 75. Middle East & Africa Vaccine Conjugate Revenue Forecast by Country (2025-2030) & ($ millions)
Table 76. Global Vaccine Conjugate Sales Forecast by Type (2025-2030) & (K Doses)
Table 77. Global Vaccine Conjugate Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 78. Global Vaccine Conjugate Sales Forecast by Application (2025-2030) & (K Doses)
Table 79. Global Vaccine Conjugate Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 80. Pfizer Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 81. Pfizer Vaccine Conjugate Product Portfolios and Specifications
Table 82. Pfizer Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 83. Pfizer Main Business
Table 84. Pfizer Latest Developments
Table 85. GSK Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 86. GSK Vaccine Conjugate Product Portfolios and Specifications
Table 87. GSK Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 88. GSK Main Business
Table 89. GSK Latest Developments
Table 90. Sanofi Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 91. Sanofi Vaccine Conjugate Product Portfolios and Specifications
Table 92. Sanofi Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 93. Sanofi Main Business
Table 94. Sanofi Latest Developments
Table 95. Merck Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 96. Merck Vaccine Conjugate Product Portfolios and Specifications
Table 97. Merck Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 98. Merck Main Business
Table 99. Merck Latest Developments
Table 100. Walvax Biotechnology Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 101. Walvax Biotechnology Vaccine Conjugate Product Portfolios and Specifications
Table 102. Walvax Biotechnology Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 103. Walvax Biotechnology Main Business
Table 104. Walvax Biotechnology Latest Developments
Table 105. Royal (Wuxi) Bio-Pharmaceutical Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 106. Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Product Portfolios and Specifications
Table 107. Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 108. Royal (Wuxi) Bio-Pharmaceutical Main Business
Table 109. Royal (Wuxi) Bio-Pharmaceutical Latest Developments
Table 110. Bharat Biotech Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 111. Bharat Biotech Vaccine Conjugate Product Portfolios and Specifications
Table 112. Bharat Biotech Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 113. Bharat Biotech Main Business
Table 114. Bharat Biotech Latest Developments
Table 115. Zhifei Biologic Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 116. Zhifei Biologic Vaccine Conjugate Product Portfolios and Specifications
Table 117. Zhifei Biologic Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 118. Zhifei Biologic Main Business
Table 119. Zhifei Biologic Latest Developments
Table 120. Chengdu Olymvax Biopharmaceuticals Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 121. Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Product Portfolios and Specifications
Table 122. Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 123. Chengdu Olymvax Biopharmaceuticals Main Business
Table 124. Chengdu Olymvax Biopharmaceuticals Latest Developments
Table 125. Beijing Minhai Biotechnology Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 126. Beijing Minhai Biotechnology Vaccine Conjugate Product Portfolios and Specifications
Table 127. Beijing Minhai Biotechnology Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 128. Beijing Minhai Biotechnology Main Business
Table 129. Beijing Minhai Biotechnology Latest Developments
Table 130. CanSinoBIO Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 131. CanSinoBIO Vaccine Conjugate Product Portfolios and Specifications
Table 132. CanSinoBIO Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 133. CanSinoBIO Main Business
Table 134. CanSinoBIO Latest Developments
Table 135. Beijing Xiangrui Biological Products Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 136. Beijing Xiangrui Biological Products Vaccine Conjugate Product Portfolios and Specifications
Table 137. Beijing Xiangrui Biological Products Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 138. Beijing Xiangrui Biological Products Main Business
Table 139. Beijing Xiangrui Biological Products Latest Developments
Table 1. Vaccine Conjugate Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Vaccine Conjugate Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Hib Vaccine
Table 4. Major Players of Meningococcal Vaccine
Table 5. Major Players of Pneumococcal Vaccine
Table 6. Major Players of Others
Table 7. Global Vaccine Conjugate Sales by Type (2019-2024) & (K Doses)
Table 8. Global Vaccine Conjugate Sales Market Share by Type (2019-2024)
Table 9. Global Vaccine Conjugate Revenue by Type (2019-2024) & ($ million)
Table 10. Global Vaccine Conjugate Revenue Market Share by Type (2019-2024)
Table 11. Global Vaccine Conjugate Sale Price by Type (2019-2024) & (US$/Dose)
Table 12. Global Vaccine Conjugate Sales by Application (2019-2024) & (K Doses)
Table 13. Global Vaccine Conjugate Sales Market Share by Application (2019-2024)
Table 14. Global Vaccine Conjugate Revenue by Application (2019-2024)
Table 15. Global Vaccine Conjugate Revenue Market Share by Application (2019-2024)
Table 16. Global Vaccine Conjugate Sale Price by Application (2019-2024) & (US$/Dose)
Table 17. Global Vaccine Conjugate Sales by Company (2019-2024) & (K Doses)
Table 18. Global Vaccine Conjugate Sales Market Share by Company (2019-2024)
Table 19. Global Vaccine Conjugate Revenue by Company (2019-2024) ($ Millions)
Table 20. Global Vaccine Conjugate Revenue Market Share by Company (2019-2024)
Table 21. Global Vaccine Conjugate Sale Price by Company (2019-2024) & (US$/Dose)
Table 22. Key Manufacturers Vaccine Conjugate Producing Area Distribution and Sales Area
Table 23. Players Vaccine Conjugate Products Offered
Table 24. Vaccine Conjugate Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Vaccine Conjugate Sales by Geographic Region (2019-2024) & (K Doses)
Table 28. Global Vaccine Conjugate Sales Market Share Geographic Region (2019-2024)
Table 29. Global Vaccine Conjugate Revenue by Geographic Region (2019-2024) & ($ millions)
Table 30. Global Vaccine Conjugate Revenue Market Share by Geographic Region (2019-2024)
Table 31. Global Vaccine Conjugate Sales by Country/Region (2019-2024) & (K Doses)
Table 32. Global Vaccine Conjugate Sales Market Share by Country/Region (2019-2024)
Table 33. Global Vaccine Conjugate Revenue by Country/Region (2019-2024) & ($ millions)
Table 34. Global Vaccine Conjugate Revenue Market Share by Country/Region (2019-2024)
Table 35. Americas Vaccine Conjugate Sales by Country (2019-2024) & (K Doses)
Table 36. Americas Vaccine Conjugate Sales Market Share by Country (2019-2024)
Table 37. Americas Vaccine Conjugate Revenue by Country (2019-2024) & ($ Millions)
Table 38. Americas Vaccine Conjugate Revenue Market Share by Country (2019-2024)
Table 39. Americas Vaccine Conjugate Sales by Type (2019-2024) & (K Doses)
Table 40. Americas Vaccine Conjugate Sales by Application (2019-2024) & (K Doses)
Table 41. APAC Vaccine Conjugate Sales by Region (2019-2024) & (K Doses)
Table 42. APAC Vaccine Conjugate Sales Market Share by Region (2019-2024)
Table 43. APAC Vaccine Conjugate Revenue by Region (2019-2024) & ($ Millions)
Table 44. APAC Vaccine Conjugate Revenue Market Share by Region (2019-2024)
Table 45. APAC Vaccine Conjugate Sales by Type (2019-2024) & (K Doses)
Table 46. APAC Vaccine Conjugate Sales by Application (2019-2024) & (K Doses)
Table 47. Europe Vaccine Conjugate Sales by Country (2019-2024) & (K Doses)
Table 48. Europe Vaccine Conjugate Sales Market Share by Country (2019-2024)
Table 49. Europe Vaccine Conjugate Revenue by Country (2019-2024) & ($ Millions)
Table 50. Europe Vaccine Conjugate Revenue Market Share by Country (2019-2024)
Table 51. Europe Vaccine Conjugate Sales by Type (2019-2024) & (K Doses)
Table 52. Europe Vaccine Conjugate Sales by Application (2019-2024) & (K Doses)
Table 53. Middle East & Africa Vaccine Conjugate Sales by Country (2019-2024) & (K Doses)
Table 54. Middle East & Africa Vaccine Conjugate Sales Market Share by Country (2019-2024)
Table 55. Middle East & Africa Vaccine Conjugate Revenue by Country (2019-2024) & ($ Millions)
Table 56. Middle East & Africa Vaccine Conjugate Revenue Market Share by Country (2019-2024)
Table 57. Middle East & Africa Vaccine Conjugate Sales by Type (2019-2024) & (K Doses)
Table 58. Middle East & Africa Vaccine Conjugate Sales by Application (2019-2024) & (K Doses)
Table 59. Key Market Drivers & Growth Opportunities of Vaccine Conjugate
Table 60. Key Market Challenges & Risks of Vaccine Conjugate
Table 61. Key Industry Trends of Vaccine Conjugate
Table 62. Vaccine Conjugate Raw Material
Table 63. Key Suppliers of Raw Materials
Table 64. Vaccine Conjugate Distributors List
Table 65. Vaccine Conjugate Customer List
Table 66. Global Vaccine Conjugate Sales Forecast by Region (2025-2030) & (K Doses)
Table 67. Global Vaccine Conjugate Revenue Forecast by Region (2025-2030) & ($ millions)
Table 68. Americas Vaccine Conjugate Sales Forecast by Country (2025-2030) & (K Doses)
Table 69. Americas Vaccine Conjugate Revenue Forecast by Country (2025-2030) & ($ millions)
Table 70. APAC Vaccine Conjugate Sales Forecast by Region (2025-2030) & (K Doses)
Table 71. APAC Vaccine Conjugate Revenue Forecast by Region (2025-2030) & ($ millions)
Table 72. Europe Vaccine Conjugate Sales Forecast by Country (2025-2030) & (K Doses)
Table 73. Europe Vaccine Conjugate Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. Middle East & Africa Vaccine Conjugate Sales Forecast by Country (2025-2030) & (K Doses)
Table 75. Middle East & Africa Vaccine Conjugate Revenue Forecast by Country (2025-2030) & ($ millions)
Table 76. Global Vaccine Conjugate Sales Forecast by Type (2025-2030) & (K Doses)
Table 77. Global Vaccine Conjugate Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 78. Global Vaccine Conjugate Sales Forecast by Application (2025-2030) & (K Doses)
Table 79. Global Vaccine Conjugate Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 80. Pfizer Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 81. Pfizer Vaccine Conjugate Product Portfolios and Specifications
Table 82. Pfizer Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 83. Pfizer Main Business
Table 84. Pfizer Latest Developments
Table 85. GSK Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 86. GSK Vaccine Conjugate Product Portfolios and Specifications
Table 87. GSK Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 88. GSK Main Business
Table 89. GSK Latest Developments
Table 90. Sanofi Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 91. Sanofi Vaccine Conjugate Product Portfolios and Specifications
Table 92. Sanofi Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 93. Sanofi Main Business
Table 94. Sanofi Latest Developments
Table 95. Merck Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 96. Merck Vaccine Conjugate Product Portfolios and Specifications
Table 97. Merck Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 98. Merck Main Business
Table 99. Merck Latest Developments
Table 100. Walvax Biotechnology Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 101. Walvax Biotechnology Vaccine Conjugate Product Portfolios and Specifications
Table 102. Walvax Biotechnology Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 103. Walvax Biotechnology Main Business
Table 104. Walvax Biotechnology Latest Developments
Table 105. Royal (Wuxi) Bio-Pharmaceutical Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 106. Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Product Portfolios and Specifications
Table 107. Royal (Wuxi) Bio-Pharmaceutical Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 108. Royal (Wuxi) Bio-Pharmaceutical Main Business
Table 109. Royal (Wuxi) Bio-Pharmaceutical Latest Developments
Table 110. Bharat Biotech Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 111. Bharat Biotech Vaccine Conjugate Product Portfolios and Specifications
Table 112. Bharat Biotech Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 113. Bharat Biotech Main Business
Table 114. Bharat Biotech Latest Developments
Table 115. Zhifei Biologic Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 116. Zhifei Biologic Vaccine Conjugate Product Portfolios and Specifications
Table 117. Zhifei Biologic Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 118. Zhifei Biologic Main Business
Table 119. Zhifei Biologic Latest Developments
Table 120. Chengdu Olymvax Biopharmaceuticals Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 121. Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Product Portfolios and Specifications
Table 122. Chengdu Olymvax Biopharmaceuticals Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 123. Chengdu Olymvax Biopharmaceuticals Main Business
Table 124. Chengdu Olymvax Biopharmaceuticals Latest Developments
Table 125. Beijing Minhai Biotechnology Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 126. Beijing Minhai Biotechnology Vaccine Conjugate Product Portfolios and Specifications
Table 127. Beijing Minhai Biotechnology Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 128. Beijing Minhai Biotechnology Main Business
Table 129. Beijing Minhai Biotechnology Latest Developments
Table 130. CanSinoBIO Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 131. CanSinoBIO Vaccine Conjugate Product Portfolios and Specifications
Table 132. CanSinoBIO Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 133. CanSinoBIO Main Business
Table 134. CanSinoBIO Latest Developments
Table 135. Beijing Xiangrui Biological Products Basic Information, Vaccine Conjugate Manufacturing Base, Sales Area and Its Competitors
Table 136. Beijing Xiangrui Biological Products Vaccine Conjugate Product Portfolios and Specifications
Table 137. Beijing Xiangrui Biological Products Vaccine Conjugate Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2019-2024)
Table 138. Beijing Xiangrui Biological Products Main Business
Table 139. Beijing Xiangrui Biological Products Latest Developments
LIST OF FIGURES
Figure 1. Picture of Vaccine Conjugate
Figure 2. Vaccine Conjugate Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Vaccine Conjugate Sales Growth Rate 2019-2030 (K Doses)
Figure 7. Global Vaccine Conjugate Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Vaccine Conjugate Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Hib Vaccine
Figure 10. Product Picture of Meningococcal Vaccine
Figure 11. Product Picture of Pneumococcal Vaccine
Figure 12. Product Picture of Others
Figure 13. Global Vaccine Conjugate Sales Market Share by Type in 2023
Figure 14. Global Vaccine Conjugate Revenue Market Share by Type (2019-2024)
Figure 15. Vaccine Conjugate Consumed in Children
Figure 16. Global Vaccine Conjugate Market: Children (2019-2024) & (K Doses)
Figure 17. Vaccine Conjugate Consumed in Adult
Figure 18. Global Vaccine Conjugate Market: Adult (2019-2024) & (K Doses)
Figure 19. Global Vaccine Conjugate Sales Market Share by Application (2023)
Figure 20. Global Vaccine Conjugate Revenue Market Share by Application in 2023
Figure 21. Vaccine Conjugate Sales Market by Company in 2023 (K Doses)
Figure 22. Global Vaccine Conjugate Sales Market Share by Company in 2023
Figure 23. Vaccine Conjugate Revenue Market by Company in 2023 ($ Million)
Figure 24. Global Vaccine Conjugate Revenue Market Share by Company in 2023
Figure 25. Global Vaccine Conjugate Sales Market Share by Geographic Region (2019-2024)
Figure 26. Global Vaccine Conjugate Revenue Market Share by Geographic Region in 2023
Figure 27. Americas Vaccine Conjugate Sales 2019-2024 (K Doses)
Figure 28. Americas Vaccine Conjugate Revenue 2019-2024 ($ Millions)
Figure 29. APAC Vaccine Conjugate Sales 2019-2024 (K Doses)
Figure 30. APAC Vaccine Conjugate Revenue 2019-2024 ($ Millions)
Figure 31. Europe Vaccine Conjugate Sales 2019-2024 (K Doses)
Figure 32. Europe Vaccine Conjugate Revenue 2019-2024 ($ Millions)
Figure 33. Middle East & Africa Vaccine Conjugate Sales 2019-2024 (K Doses)
Figure 34. Middle East & Africa Vaccine Conjugate Revenue 2019-2024 ($ Millions)
Figure 35. Americas Vaccine Conjugate Sales Market Share by Country in 2023
Figure 36. Americas Vaccine Conjugate Revenue Market Share by Country in 2023
Figure 37. Americas Vaccine Conjugate Sales Market Share by Type (2019-2024)
Figure 38. Americas Vaccine Conjugate Sales Market Share by Application (2019-2024)
Figure 39. United States Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 40. Canada Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 41. Mexico Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 42. Brazil Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 43. APAC Vaccine Conjugate Sales Market Share by Region in 2023
Figure 44. APAC Vaccine Conjugate Revenue Market Share by Regions in 2023
Figure 45. APAC Vaccine Conjugate Sales Market Share by Type (2019-2024)
Figure 46. APAC Vaccine Conjugate Sales Market Share by Application (2019-2024)
Figure 47. China Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 48. Japan Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 49. South Korea Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 50. Southeast Asia Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 51. India Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 52. Australia Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 53. China Taiwan Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 54. Europe Vaccine Conjugate Sales Market Share by Country in 2023
Figure 55. Europe Vaccine Conjugate Revenue Market Share by Country in 2023
Figure 56. Europe Vaccine Conjugate Sales Market Share by Type (2019-2024)
Figure 57. Europe Vaccine Conjugate Sales Market Share by Application (2019-2024)
Figure 58. Germany Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 59. France Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 60. UK Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 61. Italy Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 62. Russia Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 63. Middle East & Africa Vaccine Conjugate Sales Market Share by Country in 2023
Figure 64. Middle East & Africa Vaccine Conjugate Revenue Market Share by Country in 2023
Figure 65. Middle East & Africa Vaccine Conjugate Sales Market Share by Type (2019-2024)
Figure 66. Middle East & Africa Vaccine Conjugate Sales Market Share by Application (2019-2024)
Figure 67. Egypt Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 68. South Africa Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 69. Israel Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 70. Turkey Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 71. GCC Country Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 72. Manufacturing Cost Structure Analysis of Vaccine Conjugate in 2023
Figure 73. Manufacturing Process Analysis of Vaccine Conjugate
Figure 74. Industry Chain Structure of Vaccine Conjugate
Figure 75. Channels of Distribution
Figure 76. Global Vaccine Conjugate Sales Market Forecast by Region (2025-2030)
Figure 77. Global Vaccine Conjugate Revenue Market Share Forecast by Region (2025-2030)
Figure 78. Global Vaccine Conjugate Sales Market Share Forecast by Type (2025-2030)
Figure 79. Global Vaccine Conjugate Revenue Market Share Forecast by Type (2025-2030)
Figure 80. Global Vaccine Conjugate Sales Market Share Forecast by Application (2025-2030)
Figure 81. Global Vaccine Conjugate Revenue Market Share Forecast by Application (2025-2030)
Figure 1. Picture of Vaccine Conjugate
Figure 2. Vaccine Conjugate Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Vaccine Conjugate Sales Growth Rate 2019-2030 (K Doses)
Figure 7. Global Vaccine Conjugate Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Vaccine Conjugate Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Hib Vaccine
Figure 10. Product Picture of Meningococcal Vaccine
Figure 11. Product Picture of Pneumococcal Vaccine
Figure 12. Product Picture of Others
Figure 13. Global Vaccine Conjugate Sales Market Share by Type in 2023
Figure 14. Global Vaccine Conjugate Revenue Market Share by Type (2019-2024)
Figure 15. Vaccine Conjugate Consumed in Children
Figure 16. Global Vaccine Conjugate Market: Children (2019-2024) & (K Doses)
Figure 17. Vaccine Conjugate Consumed in Adult
Figure 18. Global Vaccine Conjugate Market: Adult (2019-2024) & (K Doses)
Figure 19. Global Vaccine Conjugate Sales Market Share by Application (2023)
Figure 20. Global Vaccine Conjugate Revenue Market Share by Application in 2023
Figure 21. Vaccine Conjugate Sales Market by Company in 2023 (K Doses)
Figure 22. Global Vaccine Conjugate Sales Market Share by Company in 2023
Figure 23. Vaccine Conjugate Revenue Market by Company in 2023 ($ Million)
Figure 24. Global Vaccine Conjugate Revenue Market Share by Company in 2023
Figure 25. Global Vaccine Conjugate Sales Market Share by Geographic Region (2019-2024)
Figure 26. Global Vaccine Conjugate Revenue Market Share by Geographic Region in 2023
Figure 27. Americas Vaccine Conjugate Sales 2019-2024 (K Doses)
Figure 28. Americas Vaccine Conjugate Revenue 2019-2024 ($ Millions)
Figure 29. APAC Vaccine Conjugate Sales 2019-2024 (K Doses)
Figure 30. APAC Vaccine Conjugate Revenue 2019-2024 ($ Millions)
Figure 31. Europe Vaccine Conjugate Sales 2019-2024 (K Doses)
Figure 32. Europe Vaccine Conjugate Revenue 2019-2024 ($ Millions)
Figure 33. Middle East & Africa Vaccine Conjugate Sales 2019-2024 (K Doses)
Figure 34. Middle East & Africa Vaccine Conjugate Revenue 2019-2024 ($ Millions)
Figure 35. Americas Vaccine Conjugate Sales Market Share by Country in 2023
Figure 36. Americas Vaccine Conjugate Revenue Market Share by Country in 2023
Figure 37. Americas Vaccine Conjugate Sales Market Share by Type (2019-2024)
Figure 38. Americas Vaccine Conjugate Sales Market Share by Application (2019-2024)
Figure 39. United States Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 40. Canada Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 41. Mexico Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 42. Brazil Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 43. APAC Vaccine Conjugate Sales Market Share by Region in 2023
Figure 44. APAC Vaccine Conjugate Revenue Market Share by Regions in 2023
Figure 45. APAC Vaccine Conjugate Sales Market Share by Type (2019-2024)
Figure 46. APAC Vaccine Conjugate Sales Market Share by Application (2019-2024)
Figure 47. China Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 48. Japan Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 49. South Korea Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 50. Southeast Asia Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 51. India Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 52. Australia Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 53. China Taiwan Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 54. Europe Vaccine Conjugate Sales Market Share by Country in 2023
Figure 55. Europe Vaccine Conjugate Revenue Market Share by Country in 2023
Figure 56. Europe Vaccine Conjugate Sales Market Share by Type (2019-2024)
Figure 57. Europe Vaccine Conjugate Sales Market Share by Application (2019-2024)
Figure 58. Germany Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 59. France Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 60. UK Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 61. Italy Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 62. Russia Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 63. Middle East & Africa Vaccine Conjugate Sales Market Share by Country in 2023
Figure 64. Middle East & Africa Vaccine Conjugate Revenue Market Share by Country in 2023
Figure 65. Middle East & Africa Vaccine Conjugate Sales Market Share by Type (2019-2024)
Figure 66. Middle East & Africa Vaccine Conjugate Sales Market Share by Application (2019-2024)
Figure 67. Egypt Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 68. South Africa Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 69. Israel Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 70. Turkey Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 71. GCC Country Vaccine Conjugate Revenue Growth 2019-2024 ($ Millions)
Figure 72. Manufacturing Cost Structure Analysis of Vaccine Conjugate in 2023
Figure 73. Manufacturing Process Analysis of Vaccine Conjugate
Figure 74. Industry Chain Structure of Vaccine Conjugate
Figure 75. Channels of Distribution
Figure 76. Global Vaccine Conjugate Sales Market Forecast by Region (2025-2030)
Figure 77. Global Vaccine Conjugate Revenue Market Share Forecast by Region (2025-2030)
Figure 78. Global Vaccine Conjugate Sales Market Share Forecast by Type (2025-2030)
Figure 79. Global Vaccine Conjugate Revenue Market Share Forecast by Type (2025-2030)
Figure 80. Global Vaccine Conjugate Sales Market Share Forecast by Application (2025-2030)
Figure 81. Global Vaccine Conjugate Revenue Market Share Forecast by Application (2025-2030)
